Voruciclib hydrochloride

Name: Voruciclib hydrochloride
Brand: TargetMol
SKU: T13309
Rating: 4.5 (1 reviews)

还可以

产品编号 T13309Cas号 1000023-05-1

Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).

还可以

产品编号 T13309Cas号 1000023-05-1

Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

联系我们获取更多批次信息

资源下载

产品介绍

生物活性

产品描述	Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).
靶点活性	CDK6-CyclinD1:2.92 nM (ki), CDK9-CyclinT2:0.626 nM (ki), CDK1-CyclinB:5.4 nM (ki), CDK9-CyclinT1:1.68 nM (ki), CDK4-CyclinD1:3.96 nM (ki), CDK1-CyclinA:9.1 nM (ki)
体外活性	In both ABC and GCB subtypes, Voruciclib hydrochloride (0.5-5 μM; 6 hours) shows targeted downregulation of MCL-1 . Ki values for each target such as CDK9/cyc T2, CDK9/cyc T1, CDK6/cyc D1, CDK4/cyc D1, CDK1/cyc B, and CDK1/cyc A for Voruciclib hydrochloride are 0.626 nM, 1.68 nM, 2.92 nM, 3.96 nM, 5.4 nM, 9.1 nM, respectively.
体内活性	Combination of Venetoclax (10 mpk, 1 mpk, 50 mpk, 25 mpk in U2932, RIVA, SU-DHL-4 and NU-DHL-1, respectively) and Voruciclib hydrochloride (200 mpk; Oral gavage) leads to enhance tumor growth inhibition compared to either drug alone in U2932, RIVA, SU-DHL-4 (six days per week for 4 weeks), and NU-DHL-1 models (five days per week for 3 weeks) of DLBCL.

化学信息

储存&溶解度

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

溶解度信息

DMSO: 250 mg/mL (493.78 mM), Sonication is recommended.

溶液配制表

DMSO